Objective To observe clinical efficacy of Telmisartan combined with Amiodarone in the treatment of atrial fibrillation complicating acute myocardial infarction (AMI). Methods 130 patients with atrial fibrillation complicating AMI admitted to Zhengzhou Hospital of Traditional Chinese Medicine from January 2008 to March 2011 were selected as subjects and divided into observation group and control group, with 65 cases in each group. Both groups were given Amiodarone infusion and the observation group was given Telmisartan in addition. Clinical efficacies of the two groups were compared. Results Cardioversion rates showed no significant difference between the two groups 24 h and 3 d af-ter treatment (P > 0.05), while those after 5 d and 7 d treatment were significantly different between the two groups (P < 0.05). Hospitalized days of the two groups were not significantly different (P > 0.05), but hospital mortality of obser-vation group was significantly lower than that of control group (P < 0.05). Adverse reactions were mild, liver and kid-ney function and hemorheology showed no obvious abnormalities after completion of treatment. Conclusion Telmisar-tan combined with Amiodarone has satisfactory results in the treatment of atrial fibrillation complicating AMI. It can improve short-term cardioversion rate and reduce mortality, with high safety, thus it is worthy of clinical application.%目的 观察丹参酮治疗早期心肾综合征的疗效及其对N端前体脑钠肽(NT-proBNP)和胱抑素C(Cys C)水平的影响.方法 选择2008年1月～2012年11月在上海市第一人民医院宝山分院就诊的早期心肾综合征患者60例,将其随机分为观察组和对照组,每组各30例.对照组予以综合治理,观察组在对照组的基础上予以丹参酮.观察两组的疗效及其治疗前后的肾小球滤过率(GRF)、尿白蛋白分泌率(UAER)、NT-proBNP和Cys C水平的变化.结果 两组治疗后,观察组的总有效率为80.00%,而对照组的总有效率为53.33%,观察组的疗效优于对照组,差异有统计学意义(P ＜ 0.05).两组治疗7、14 d后,两组的GRF、UAER、NT-proBNP和Cys C水平较治疗前明显降低(P ＜ 0.01),观察组的降低水平较对照组更为明显,差异有统计学意义(P ＜ 0.05或P ＜ 0.01).结论 丹参酮治疗早期心肾综合征患者的疗效显著,其机制可能与降低NT-proBNP和Cys C水平有关.
展开▼
